cilostazol has been researched along with Diabetes Mellitus in 16 studies
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " She had taken Cilostazol for the first time, for only one day, so the diagnosis of acute kidney injury, probably drug-induced acute interstitial nephritis, due to Cilostazol use, was made." | 9.22 | Cilostazol-induced Acute Kidney Injury in A Patient With Diabetic Foot Ulcer: A Case Report and Review of Literature. ( Kabiri Naeini, E; Mazaheri-Tehrani, S; Shahidi, S, 2022) |
| "Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia." | 9.15 | Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| " Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel." | 7.83 | Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016) |
| "Cilostazol is a platelet inhibitor which when added to aspirin and clopidogrel has shown to reduce the risk of recurrent ischaemic events without an increase in bleeding." | 6.76 | Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. ( Angiolillo, DJ; Bass, TA; Box, LC; Capodanno, D; Capranzano, P; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Guzman, LA; Sumner, S; Ueno, M; Zenni, M, 2011) |
| " She had taken Cilostazol for the first time, for only one day, so the diagnosis of acute kidney injury, probably drug-induced acute interstitial nephritis, due to Cilostazol use, was made." | 5.22 | Cilostazol-induced Acute Kidney Injury in A Patient With Diabetic Foot Ulcer: A Case Report and Review of Literature. ( Kabiri Naeini, E; Mazaheri-Tehrani, S; Shahidi, S, 2022) |
| "Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia." | 5.15 | Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "Diabetic and non-diabetic patients with intermittent claudication respond favourably to cilostazol, with no significant difference in their overall response." | 5.10 | Cilostazol treatment of claudication in diabetic patients. ( Cariski, AT; Hittel, N; Rendell, M; Zhang, P, 2002) |
| "The aim of this study was to evaluate the effect of a three-month cilostazol treatment on the health-related quality of life and on the lower-limb functional capacity in diabetic (DM) and non-diabetic patients (NDM) with intermittent claudication in the clinical practice." | 3.96 | Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients ( Farkas, K; Járai, Z; Kolossváry, E, 2020) |
| " The circulating SP-D level was affected by sex, diabetes mellitus, and cilostazol prescription." | 3.88 | Circulating Surfactant Protein-D Is Associated With Clinical Outcomes in Peripheral Artery Disease Patients Following Endovascular Therapy. ( Arimoto, T; Kubota, I; Miyamoto, T; Nishiyama, S; Otaki, Y; Shishido, T; Sugai, T; Takahashi, H; Watanabe, M; Watanabe, T; Yamanaka, T; Yokoyama, M, 2018) |
| " Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel." | 3.83 | Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016) |
| "Cilostazol is a platelet inhibitor which when added to aspirin and clopidogrel has shown to reduce the risk of recurrent ischaemic events without an increase in bleeding." | 2.76 | Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. ( Angiolillo, DJ; Bass, TA; Box, LC; Capodanno, D; Capranzano, P; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Guzman, LA; Sumner, S; Ueno, M; Zenni, M, 2011) |
| "Cilostazol was administered 1 hour after 2VO, and thereafter at a continuous oral dose of 60 mg/kg per day." | 1.37 | Cilostazol minimizes venous ischemic injury in diabetic and normal rats. ( Horiuchi, K; Nakamura, M; Nakase, H; Nishimura, F; Takeshima, Y; Wajima, D, 2011) |
| "Cilostazol was then added in a cumulative manner (680-2,720 microg/L), and the tension generated was recorded." | 1.33 | Effects of cilostazol on human venous smooth muscle. ( Becker, RW; Kline, RA; Lusis, E; Sohn, RL, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shahidi, S | 1 |
| Kabiri Naeini, E | 1 |
| Mazaheri-Tehrani, S | 1 |
| Cha, JJ | 1 |
| Cho, JY | 1 |
| Lim, S | 1 |
| Kim, JH | 2 |
| Joo, HJ | 1 |
| Park, JH | 2 |
| Hong, SJ | 1 |
| Lim, DS | 1 |
| Kook, H | 1 |
| Lee, SH | 1 |
| Ko, YG | 1 |
| Min, PK | 1 |
| Lee, JH | 2 |
| Yoon, CH | 1 |
| Chae, IH | 1 |
| Lee, SW | 2 |
| Lee, SR | 1 |
| Choi, SH | 1 |
| Koh, YS | 1 |
| Yu, CW | 1 |
| Colak, B | 1 |
| Orhan, A | 1 |
| Ece, I | 1 |
| Yormaz, S | 1 |
| Yilmaz, H | 1 |
| Sahin, M | 1 |
| Farkas, K | 1 |
| Kolossváry, E | 1 |
| Járai, Z | 1 |
| Otaki, Y | 1 |
| Watanabe, T | 1 |
| Takahashi, H | 1 |
| Sugai, T | 1 |
| Yokoyama, M | 1 |
| Nishiyama, S | 1 |
| Arimoto, T | 1 |
| Shishido, T | 1 |
| Miyamoto, T | 1 |
| Yamanaka, T | 1 |
| Kubota, I | 1 |
| Watanabe, M | 1 |
| Nakagawa, I | 1 |
| Park, HS | 1 |
| Yokoyama, S | 1 |
| Wada, T | 1 |
| Hironaka, Y | 1 |
| Motoyama, Y | 1 |
| Takayama, K | 1 |
| Kichikawa, K | 1 |
| Nakase, H | 2 |
| Zuliani Mauro, MF | 1 |
| Mangione, JA | 1 |
| Costa, JR | 1 |
| Costa, R | 1 |
| Piva E Mattos, LA | 1 |
| Staico, R | 1 |
| Feres, F | 1 |
| Siqueira, D | 1 |
| Sousa, A | 1 |
| Abizaid, A | 1 |
| Wajima, D | 1 |
| Nakamura, M | 1 |
| Horiuchi, K | 1 |
| Takeshima, Y | 1 |
| Nishimura, F | 1 |
| Angiolillo, DJ | 1 |
| Capranzano, P | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 1 |
| Capodanno, D | 1 |
| Dharmashankar, K | 1 |
| Darlington, A | 1 |
| Sumner, S | 1 |
| Desai, B | 1 |
| Charlton, RK | 1 |
| Box, LC | 1 |
| Zenni, M | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Ueno, H | 1 |
| Koyama, H | 1 |
| Mima, Y | 1 |
| Fukumoto, S | 1 |
| Tanaka, S | 1 |
| Shoji, T | 2 |
| Emoto, M | 1 |
| Nishizawa, Y | 1 |
| Inaba, M | 1 |
| Rendell, M | 1 |
| Cariski, AT | 1 |
| Hittel, N | 1 |
| Zhang, P | 1 |
| Becker, RW | 1 |
| Lusis, E | 1 |
| Sohn, RL | 1 |
| Kline, RA | 1 |
| Park, SW | 1 |
| Kim, YH | 1 |
| Yun, SC | 1 |
| Park, DW | 1 |
| Lee, CW | 1 |
| Hong, MK | 1 |
| Kim, HS | 1 |
| Ko, JK | 1 |
| Choi, SW | 1 |
| Seong, IW | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Chun, KJ | 1 |
| Park, SJ | 1 |
| Hayakawa, T | 1 |
| Shouzu, A | 1 |
| Nishikawa, M | 1 |
| Miyake, Y | 1 |
| Shimizu, H | 1 |
| Omoto, S | 1 |
| Inada, M | 1 |
| Hiatt, WR | 2 |
| Nehler, MR | 1 |
| Regensteiner, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for cilostazol and Diabetes Mellitus
| Article | Year |
|---|---|
Cilostazol-induced Acute Kidney Injury in A Patient With Diabetic Foot Ulcer: A Case Report and Review of Literature.
Topics: Acute Kidney Injury; Cilostazol; Creatinine; Diabetes Mellitus; Diabetic Foot; Female; Humans; Middl | 2022 |
Peripheral arterial disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Diabetes Complications; Diabetes Mellitus; Dis | 2001 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
6 trials available for cilostazol and Diabetes Mellitus
| Article | Year |
|---|---|
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; Chemotherapy, Adjuvant; Cilostazol; Clopidogrel; Cross-Over Studies; | 2011 |
Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial.
Topics: Aged; Aspirin; Brain Ischemia; Cholesterol, LDL; Cilostazol; Diabetes Mellitus; Endothelium, Vascula | 2011 |
Cilostazol treatment of claudication in diabetic patients.
Topics: Adult; Cilostazol; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Humans; I | 2002 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Effects of beraprost and cilostazol and renal function on serum thrombomodulin levels in diabetic patients.
Topics: Cilostazol; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Epoprostenol; Humans; Kidney Func | 2000 |
7 other studies available for cilostazol and Diabetes Mellitus
| Article | Year |
|---|---|
Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease.
Topics: Cilostazol; Diabetes Mellitus; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; | 2023 |
Comparison of the effects of cilostazol and aspirin on wound healing in patients with diabetic foot ulcer and peripheral artery disease.
Topics: Aspirin; Cilostazol; Diabetes Mellitus; Diabetic Foot; Humans; Peripheral Arterial Disease; Retrospe | 2020 |
Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients
Topics: Aged; Case-Control Studies; Cilostazol; Diabetes Complications; Diabetes Mellitus; Female; Humans; I | 2020 |
Circulating Surfactant Protein-D Is Associated With Clinical Outcomes in Peripheral Artery Disease Patients Following Endovascular Therapy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cilostazol; Diabetes Mellitus; Endovascular Proced | 2018 |
Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Dia | 2016 |
Cilostazol minimizes venous ischemic injury in diabetic and normal rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Brain Infarction; Cerebrovascular Circulation; Cilos | 2011 |
Effects of cilostazol on human venous smooth muscle.
Topics: Cilostazol; Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Hyper | 2005 |